NCT01445613CompletedNot Applicable
CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
Abbott Medical Devices1 site in 1 country1,203 target enrollmentStarted: October 1, 2011Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Abbott Medical Devices
- Enrollment
- 1,203
- Locations
- 1
- Primary Endpoint
- Composite Rate of Peri-procedural (Within 30 Days of the Procedure) Death and Stroke, Plus Ipsilateral Stroke Between Day 31 and 1 Year (365 Days)
Study Overview
Brief Summary
The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject must be ≥ 18 years of age.
- •Subject does not have any condition that limits their anticipated survival to less than 3 years.
- •Subject or a legally authorized representative must provide written informed consent prior to any trial related procedure.
- •Subjects with neurological symptoms within 180 days of the procedure and ≥ 70% stenosis of the common or internal carotid artery by ultrasound or ≥ 50% stenosis of the common or internal carotid artery by angiogram - OR-
- •Subjects without neurological symptoms within 180 days of the procedure and ≥ 70% stenosis of the common or internal carotid artery by ultrasound or ≥ 60% stenosis of the common or internal carotid artery by angiogram.
- •Subject with all the following target vessel characteristics:
- •Discrete lesion in internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA).
- •Vessel diameter ≥ 4.0 mm and ≤ 9.0 mm from reference or contralateral artery.
- •Absence of excessive vessel tortuosity that would impede delivery of devices.
- •Subject must agree not to participate in any other clinical trial for a period of 1 year following the index procedure.
Exclusion Criteria
- •Subjects with anatomic or clinical conditions which make them at high risk for adverse events from carotid endarterectomy (CEA).
- •Subject with Hgb <10.g/dl or platelet count < 125,000 µl or has heparin-associated thrombocytopenia. For subjects on Coumadin (Warfarin) and for subjects with a platelet or coagulation disorder: Has an international normalized ratio (INR) > 1.
- •Subject has active bleeding diathesis or coagulopathy or subject would refuse blood transfusions.
- •Subject is currently on a list for major organ transplantation (i.e., heart, lung, liver, kidney) or is being evaluated for such.
- •Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.
- •Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
Arms & Interventions
RX Acculink Carotid Stent System (RX Acculink)
Other
Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
Intervention: RX Acculink Carotid Stent System (RX Acculink) (Device)
Outcomes
Primary Outcomes
Composite Rate of Peri-procedural (Within 30 Days of the Procedure) Death and Stroke, Plus Ipsilateral Stroke Between Day 31 and 1 Year (365 Days)
Time Frame: 0 to 365 days
Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Between 31 and 365 Days
Time Frame: 365 days
Secondary Outcomes
- Composite of Peri-procedural Death and Stroke by Symptomatic Status(30 days)
- Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Symptomatic Status(365 days)
- Death and All Stroke(30 Days)
- Composite of Peri-procedural Death and Stroke by Age(30 days)
- Freedom From Death and Stroke Within 30 Days and Ipsilateral Stroke Through 1 Year by Age(365 days)
- Freedom From Clinically Driven Target Lesion Revascularization(365 days)
- Clinical Success(30 days)
- Freedom From Clinically Driven Target Lesion Revascularization(30 days)
- Freedom From Clinically Driven Target Lesion Revascularization(180 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™Thromboembolic StrokeStroke PreventionTransient Ischemic AttackNCT00600327Boston Scientific Corporation488
Completed
Not Applicable
A Randomized Trial of Carotid Artery Stenting With and Without Cerebral ProtectionCarotid Artery StenosisNCT00177346University of Pittsburgh52
Completed
Not Applicable
Sundt™ Carotid Shunt Retrospective Post Market Clinical Follow-up Study (PMCF)Carotid Artery StenosisNCT03816202Integra LifeSciences Corporation100
Recruiting
Not Applicable
Carotid Artery Stent Implantation in the Treatment of Vulnerable PlaqueStent EmbolisationCarotid Artery PlaqueCarotid StenosisNCT05524207Beijing Tsinghua Chang Gung Hospital100
Completed
Phase 4
A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery DiseaseHeart DiseaseCarotid Artery DiseaseCarotid StenosisBrain Vascular AccidentNCT00178672The University of Texas Health Science Center, Houston69